Evidence map›Paper›PMID 38023556›Full record

ArticleOpen forum infectious diseases2023

Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study.

Irene Pericot-Valverde, Snehal S Lopes, Shadi Nahvi, James F Thrasher, Alison Karasz, Lynn E Taylor, Shruti H Mehta, Paula J Lum, Judith I Tsui, Kimberly Page and 8 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02824640 (Patient-Centered Models of HCV Care for People Who Inject Drugs), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02824640 nacompletednot on this map

Patient-Centered Models of HCV Care for People Who Inject Drugs

TypeinterventionalSponsorPrisma Health-UpstateRan2016 to 2021Enrolled755ConditionsHepatitis C, Medication AdherenceArmsPatient Navigation, modified Directly Observed Therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 2 countries.

Irene Pericot-ValverdeDepartment of Psychology, Clemson University, Clemson, South Carolina, USA.ORCID https://orcid.org/0000-0001-5814-0397
Snehal S LopesDepartment of Public Health Sciences, Clemson University, Clemson, South Carolina, USA.
Shadi NahviDepartment of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
James F ThrasherDepartment of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
Alison KaraszDepartment of Family Medicine & Community Health, University of Massachusetts, Worcester, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3038-2751
Lynn E TaylorCollege of Pharmacy, University of Rhode Island . Kingston, Rhode Island, USA.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Paula J LumDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Judith I TsuiDivision of General Internal Medicine, University of Washington, Seattle, Washington, USA.
Kimberly PageDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0000-0002-7120-1673
Judith FeinbergDepartment of Behavioral Medicine & Psychiatry and Department of Medicine, Infectious Diseases, West Virginia University School of Medicine, Morgantown, West Virginia, USA.ORCID https://orcid.org/0000-0003-4206-7214
Arthur Y KimDivision of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Brianna L NortonDepartment of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
Julia H ArnstenDepartment of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
Sergio Fernandez-ArtamendiDepartment of Personality, Assessment, and Psychological Treatment, Universidad de Sevilla, Seville, Spain.
Moonseong HeoDepartment of Public Health Sciences, Clemson University, Clemson, South Carolina, USA.ORCID https://orcid.org/0000-0001-7711-1209
Alain LitwinDepartment of Psychology, Clemson University, Clemson, South Carolina, USA.ORCID https://orcid.org/0000-0002-6717-0288
HERO Research Group
Clemson University · USAlbert Einstein College of Medicine · USUniversity of California, San Francisco · USHarvard University · USFamily Health Center of Worcester · USJohns Hopkins University · USPrisma Health · USUniversity of New Mexico · USUniversity of Rhode Island · USUniversity of South Carolina · USUniversity of Washington · USWest Virginia University · USUniversidad de Sevilla · ES

Funding

Mentoring investigators to improve health outcomes among persons with opioid and tobacco use disorderK24DA051807 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Shadi Nahvi · 2022 to 2026
$972k
NIDA NIH HHS K24 DA051807
6 · The paper itself

Abstract

Background: Depressive symptoms are prevalent among people who inject drugs (PWID) and people with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome. Methods: We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID, to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone. Results: The sample (n = 498) was 72.3% male, 64.2% White, and on average 43.9 years old. In patients who achieved SVR (F(3432) = 4.58; Conclusions: This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR and that drug use does not interfere with improvement in depressive symptoms.

Indexed as

DAA medicationdepressionHCVPWID

Identifiers

PMID38023556
PMCPMC10644781
OpenAlexW4387380906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.